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Abstract
Background: Contemporary challenges of prostate cancer (PCa) include overdiagnosis and overtreatment, entailing
the need for novel clinical tools to improve risk stratification and therapy selection. PCa diagnosis and
prognostication might be perfected using epigenetic biomarkers, among which aberrant DNA methylation of
microRNA promoters has not been systematically explored. Herein, we identified aberrantly methylated microRNAs
promoters in PCa and assessed its diagnostic and prognostic biomarker potential.
Methods: Using HumanMethylation450 BeadChip-based analysis differentially methylated CpGs in microRNA
promoters were identified. Promoter methylation of six microRNAs (miR-34b/c, miR-129-2, miR-152, miR-193b, miR-663a
and miR-1258) was analyzed by qMSP in three sets (180 prostatectomies, 95 urine sediments and 74 prostate biopsies).
Biomarkers’ diagnostic (validity estimates) and prognostic [disease-free (DFS) and disease-specific survival (DSS)]
performance was assessed.
Results: Significantly higher promoter methylation levels in PCa were confirmed for six candidate microRNAs. Except
for miR-152, all displayed AUC values higher than 0.90, with miR-1258 and miR-193b disclosing the best performance
(AUC = 0.99 and AUC = 0.96, respectively). In urine samples, miR-193b showed the best performance (91.6% sensitivity,
95.7% specificity, AUC = 0.96). Moreover, higher miR-129-2 independently predicted for shorter DSS and miR−34b/c
methylation levels independently predicted for shorter DFS and DSS.
Conclusions: Quantitative miR-193b, miR-129-2 and miR-34b/c promoter methylation might be clinically useful PCa
biomarkers for non-invasive detection/diagnosis and prognostication, both in tissue and urine samples.
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Background
Prostate cancer (PCa) is the most incident male cancer in
western countries, constituting the second most common
cause of cancer and the sixth leading cause of death by
cancer among men worldwide [1]. For 2012, it was esti-
mated that PCa alone accounted for 420,000 newly
diagnosed cancer cases and 101,000 of all cancer-related
deaths in European men [2]. PCa is age-related and very
heterogeneous, both molecularly and clinically, ranging
from relatively indolent to highly aggressive. It is typically
asymptomatic at its earliest stages, when adequate treat-
ment is mostly curative, in contrast with its late diagnosis,
which usually impairs a curative-intent therapeutic strategy
[3]. This led to the widespread use of serum PSA as screen-
ing tool for PCa. However, it is now commonly accepted
that this entailed overdiagnosis and overtreatment, justifying
the strong recommendation against PCa screening and
prompting the search for more effective biomarkers [4].
DNA methylation is a chemically stable and easily quanti-
fied alteration [5]. We and others have previously reported
on the use of quantitative promoter methylation of several
protein-coding genes for early diagnosis and prognostica-
tion of PCa [6]. Although several gene methylation panels
have been then developed [7, 8], both sensitivity and speci-
ficity must be perfected to allow for clinical translation.
MicroRNAs, a class of small (19–25 nucleotides) non-
coding RNA, are involved in virtually all cellular processes
and frequently deregulated in cancer cells [9], although its
abrogation due to aberrant promoter methylation has been
seldom reported [10]. Because this epigenetic alteration is
likely to be highly cancer-specific, it might constitute an
effective cancer biomarker. Thus, we aimed to explore the
potential of microRNA-coding genes promoter methylation
as diagnostic and prognostic biomarkers in PCa. Therefore,
after genome-wide screening, a set of putative tumor-
suppressor microRNAs (miR-34b/c, miR-129-2, miR-152,
miR-193b, miR-663a and miR-1258) with increased
promoter methylation levels in PCa compared to normal
prostate tissues was identified and further validated in
clinical samples.
Methods
Patients and samples collection
For the purposes of this study, three independent co-
horts of PCa patients were defined.
PCa tissue samples were prospectively collected from 180
patients with clinically localized disease, consecutively diag-
nosed and submitted to radical prostatectomy (RP) from
2001 to 2006, at Portuguese Oncology Institute of Porto
(Cohort #1). Fifteen control samples were obtained from
cystoprostatectomy specimens with bladder cancer, not
harbouring PCa nor prostatic involvement by urothelial
carcinoma (morphologically normal prostate tissue,
MNPT). After collection, tissue samples were fresh-frozen
at −80 °C and subsequently cut in a cryostat for DNA
extraction. Prostate biopsy samples were collected from 74
PCa suspects (elevated serum PSA), referred to Portuguese
Oncology Institute - Porto from 2001 to 2003 (Cohort #2).
In addition to standard diagnostic cores, a core was col-
lected from the most suspicious area, fresh-frozen at −80 °
C and subsequently cut in a cryostat for DNA extraction.
Voided urine samples from 95 PCa patients were col-
lected from 1999 to 2002 (Cohort #3). The control set is
composed of urine samples collected from 17 healthy
donors and 29 patients without urological malignancy.
Samples were centrifuged at 4,000 rpm for 20 min,
washed in PBS 1× and the pellets were frozen at −80 °C.
Clinical data was retrieved from clinical charts. Sur-
vival data was collected for patients of Cohort #1 and of
Cohort #2. Disease-specific survival (DSS) time was cal-
culated as the time elapsed since diagnosis until death or
the last follow-up. Disease-free survival (DFS) was calcu-
lated from the date of the radical prostatectomy or other
curative treatment to the date of biochemical relapse,
date of last follow-up, or death if relapse-free.
All patients enrolled (Tables 1 and 2) signed informed
consent. This study was approved by institutional review
board (CES-IPOPFG-EPE 019/08 and CES-IPOPFG-EPE
205/2013).
Nucleic acid isolation, bisulphite treatment,
HumanMethylation 450 BeadChip and qMSP analysis
DNA extracted by phenol-chloroform as described else-
where[11] was chemically modified using sodium bisulfite
with EZ DNA Methylation-Gold™ Kit (Zymo Research,
CA, USA) according to manufacturer’s protocol.
HumanMethylation450 BeadChip (Illumina, USA)
allowed for gene methylation profiling of tissue samples (5
controls and 25 tumors), using 500 ng of bisulphite-
converted DNA, according to manufacturer’s instructions.
Table 1 Clinical and pathological data of tissue and urine
samples used in this study
Prostatectomies Urine samples
Clinicopathological data MNPT PCaa Controls PCab
Patients, n 15 180 46 95
Median age, years (range) 63
(45–80)
65
(49–74)
61
(58–77)
64
(45–80)
Median PSA (ng/mL) (range) - 8.3
(3.4-23.0)
- 8.8
(3.5-20.4)
Pathological Stage
pT2 (%) - 96 (53.3) - 46 (48.4)
pT3 (%) - 84 (46.7) - 49 (51.6)
Gleason score
<7 (%) - 56 (31.1) - 37 (39.0)
≥7 (%) - 124 (68.9) - 58 (61.0)
aCohort #1; bCohort #3
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DNA methylation levels were depicted as beta-values ran-
ging from 0–1.
Validation of all candidates was performed by quanti-
tative methylation using KAPA SYBR FAST qPCR Kit
(Kapa Biosystems, MA, USA). All reactions were run in
triplicates in 384-well plates using Roche LightCycler
480 II, with β-actin (ACTB) as internal reference gene
for normalization. Primer sequences (Additional file 1:
Table S1) were designed using Methyl Primer Express
1.0 and purchased from Sigma-Aldrich (MO, USA).
Statistical analysis
For HumanMethylation 450 BeadChip data, a threshold in-
tensity with P-value ≤ 0.01 was considered for further ana-
lysis. To identify consistently differentially methylated CpG
sites, Wilcoxon rank sum paired test was performed for
normalized beta-values. P-values were adjusted using false
discovery rate, and CpGs with P-values <0.05 were selected.
In Cohort #1, pathological variables were categorized
[Gleason score (GS): <7 and ≥7; pathological stage: pT2 and
pT3]. Kruskall-Wallis and Mann–Whitney U tests allowed
for comparisons among three or more groups and between
two groups, respectively. For multiple comparisons P values
were adjusted according to Bonferroni’s correction. Spear-
man nonparametric correlation was performed to ascertain
association between methylation and PSA serum levels.
In Cohort #1 and Cohort #3, receiver operator charac-
teristics (ROC) curves were constructed by plotting true
positive rate (sensitivity) against false positive rate (1-spe-
cificity) and area under the curve (AUC) was calculated to
assess diagnostic performance. Biomarker validity esti-
mates [specificity, sensitivity, positive predictive value,
negative predictive value and accuracy] were determined
using as cut-off the highest value obtained through ROC
curve analysis [sensitivity + (1-specificity)].
In Cohort #1 and Cohort #2, DSS and DFS curves
were built using Kaplan–Meier method and the prog-
nostic significance of clinicopathological variables (clin-
ical stage, GS and serum PSA in both cohorts, and
CAPRA Score in Cohort #2) was assessed using log-
rank test. CAPRA score values were categorized as 0–2
(low-risk), 3–5 (intermediate risk) and 6–10 (high-risk)
[12]. To test the prognostic significance of miR-34b/c and
miR-129-2 promoter methylation, samples were catego-
rized based on methylation levels of each miR (using per-
centile 75 as threshold) [11]. A Cox-regression model
comprising all variables (multivariable analysis) was con-
structed. SPSS Statistics 20 (IBM, NY, USA) was used for
all statistical analyses and graphics were assembled using
GraphPad 5 Prism (GraphPad Software, CA, USA). P
values <0.05 were considered statistically significant.
Results
MicroRNA promoter hypermethylation in Radical
Prostatectomy samples (Cohort #1)
Using the 450 K array, we screened microRNA loci regu-
lated by DNA methylation in PCa. The microarray dataset
included 5 MNPT and 25 PCa tissue samples. Candidate
miRNAs were selected according to adjusted P-values and
differences in the methylated fraction between MNPT and
PCa tissues. CpG sites displaying statistically significant dif-
ferences with adjusted P-values and mean methylation <0.3
in MNPT were further considered relevant. Among these,
methylation sites located in the promoter region and in
proximity to transcription start sites (TSS) [1500 and 200
base pairs upstream of TSS (TSS200; TSS1500 region)]
were identified. For the validation study, we selected micro-
RNAs in which significant differences (P < 0.05) in methyla-
tion levels were observed at all CpG sites mapped and
differences in methylated fractions were >0.12. Thus, six
microRNAs - miR-34b/c, miR-129-2, miR-152, miR-193b,
miR-663a, and miR-1258 (Fig. 1; Table 3), were selected for
large scale validation in 15 MNPT and 180 PCa samples
(Cohort #1). In this series, overall methylation levels
remained significantly increased in PCa compared with
MNPT (Fig. 2), confirming the results of the array analysis.
Table 2 Clinical and pathological data of Cohort #2 (prostate
biopsies)
Patients, n 74
Median age, years (range) 68 (49–85)
Median PSA (ng/mL) (range) 18.22 (4.52-542)
Clinical stage
T2 (%) 48 (64.9)
T3/T4 (%) 26 (35.1)
Gleason score
<7 (%) 30 (40.5)
≥7 (%) 44 (59.5)
Follow up
Median (months) (range) 114.9 (10.3–170.1)
Patients without remission (%) 3 (4)
Biochemical recurrence (%) 29 (39.2)
Death due to PCa (%) 13 (17.6)
Therapy
Surgery (%) 17 (23.0)
ADT (%) 35 (47.3)
Radiotherapy (%) 4 (5.4)
ADT + Radiotherapy (%) 17 (23.0)
Radiotherapy + Criotherapy (%) 1 (1.3)
CAPRA Score
Low-risk (0–2) 7 (9.5)
Intermediate-risk (3–5) 26 (35.1)
High-risk (6–10) 41 (55.4)
ADT- androgen deprivation therapy
Torres-Ferreira et al. Molecular Cancer  (2017) 16:26 Page 3 of 12
To assess the diagnostic potential of microRNA promoter
methylation in PCa we performed ROC curve analysis (Fig. 2
and Table 4), which revealed AUC values ranging from 0.89
to 0.99, with miR-1258 (AUC= 0.99), miR-193b (AUC=
0.96) and miR-34b/c (AUC= 0.95) demonstrating the best
performance. Because AUC for miR-152 was lower than
0.90, it was excluded from further analyses. Concerning val-
idity estimates, miR-1258 promoter methylation levels dis-
played the highest values (97.8% sensitivity, 100% specificity)
for PCa detection. Panels composed by two or more micro-
RNAs did not improve performance (data not shown).
Then, we evaluated whether microRNA promoter me-
thylation levels were associated with clinicopathological
parameters. MiR-129-2 promoter methylation was associ-
ated with higher GS and pathological stage (P = 0.0248 and
P = 0.0245, respectively), whereas, miR-34b/c, miR-663a
and miR-1258 promoter methylation levels were only asso-
ciated with higher pathological stage (P = 0.0055, P = 0.0386
and P = 0.0303, respectively) (Fig. 3).
To determine whether microRNA promoter methyla-
tion was PCa-specific, malignant and benign tissue sam-
ples from bladder (43 and 7) and kidney (50 and 9) were
analyzed. MiR-34b/c, miR-193b and miR-1258 promoter
methylation levels were significantly higher in PCa tis-
sues compared to all other samples tested. Interestingly,
miR-129-2 and miR-663a showed higher methylation
levels in bladder cancer and were, thus, considered un-
suitable for accurate detection of PCa in urine sediments
(Additional file 2: Figure S1).
MicroRNA promoter methylation in urine sediments
(Cohort #3)
Best performing PCa-specific microRNAs - miR-34b/c,
miR-193b and miR-1258 – were then tested in urine sedi-
ments, collected without previous prostatic massage, from
PCa patients (n = 95, Cohort #3) and controls (n = 46).
Higher miR-34b/c and miR-193b methylation levels and
lower miR-1258 promoter methylation levels were depicted
in PCa patients (Fig. 4). MiR-193b promoter methylation
displayed the best performance with high sensitivity (91.6%)
and specificity (95.7%), providing an overall accuracy of
92.9% (AUC= 0.96). Moreover, the panel including both
miRs (miR-34b/c, miR-193b) augmented specificity (97.8%)
and positive predictive value (98.9%) (Table 5). Addition of
Fig. 1 HumanMethylation450 BeadChip results. The microRNAs that displayed the most significant differences between normal and neoplastic
samples were selected for further analysis. All data are presented as mean + standard deviation of the samples analyzed in each group
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miR-34b/c promoter methylation did not improve bio-
marker performance. No associations between microRNAs’
promoter methylation levels and clinicopathological param-
eters were depicted in this series.
MicroRNA promoter methylation as prognostic biomarker
(Cohorts # 1 & # 2)
Owing to its association with stage and GS, the prognostic
value of miR-34b/c and miR-129-2 promoter methylation
was further tested in the set of 180 radical prostatectomy
(Cohort #1) and in a prospective group of 74 PCa suspects
(Cohort #2).
The median follow-up in Cohort #1 was 110.1 months
(range: 2.8–169.1 months). Nine patients (5%) had died from
PCa and 50 (28%) developed biochemical recurrence. Eight-
een were never free of disease and were excluded from DFS
analysis. In this cohort, pathological stage, GS and PSA levels
significantly associated with DFS (Fig. 5A), whereas, only
pathological stage and higher GS statistically associated with
worse DSS (Fig. 6A). Remarkably, high miR-129-2 methyla-
tion levels associated with shorter DSS. In multivariable ana-
lysis, only GS and PSA levels for DFS and GS and miR-129-2
methylation for DSS retained prognostic value (Table 6).
Regarding Cohort #2, the median follow-up was
114.9 months (range: 10.3–170.1 months). Thirteen pa-
tients (17.6%) had died from PCa and 29 (39.2%) developed
biochemical recurrence. In 3 patients, serum PSA levels
>0.2 ng/ml persisted following treatment and these were
not further considered for DFS analysis. Advanced clinical
stage, higher GS, higher miR-34b/c and miR-129-2 pro-
moter methylation levels statistically associated with worse
DFS (Fig. 5B). In multivariable analysis only higher clinical
stage and high miR-34b/c promoter methylation levels in-
dependently predicted shorter DFS (Table 6). Except for
serum PSA, all clinicopathological parameters tested, as
well as miR-34b/c and miR-129-2 promoter methylation
levels associated with DSS in univariable analysis (Fig. 6B).
Similarly to DFS, in multivariable analysis only clinical stage
and high miR-34b/c promoter methylation levels independ-
ently predicted shorter DSS (Table 6).
Discussion
PCa remains one of the most prevalent neoplasms and a
leading cause of morbidity and mortality in men. Although
PSA screening has decreased the number of men diagnosed
with metastatic PCa, this was accomplished at the cost of
overdiagnosis and overtreatment of a sizeable proportion of
Table 3 MicroRNA/CpG island probe distribution derived from the Infinium HumanMethylation450 BeadChip
miR TargetID Probe Sequence Chr UCSC Refgene
Name
UCSC Refgene
Accession
UCSC Refgene
Group
UCSC CpG
Islands Name
Relation to
UCSC CpG
Island
miR-34b/c cg22879515 GTCCTCCCCGGCAGCGCCGCCCGCTG
GCCCAGCTACGCGTGTTGTGCGCTGCG
AGGCCGG[CG]GGGGTCCCGCTGGG
CCCGGGGGTGTCCTCGGGGGCC
GCTTGCGCCCAGCCATGGTAGGGC
11 MIR34B;
BTG4;
MIR34C
NR_029839;
NM_017589;
NR_029840
TSS200;
TSS1500;
TSS1500
chr11:
111383168–
111383892
Island
miR-129-2 cg14416371 GAGACACGAGTCCAGGGGCGCGG
AGGGGCGGGCAGCGCGCGGAGTG
GTGAGACTGAGCCG[CG]ATGGAACG
CGCTGGGGAGACCCAGCCTGTTC
GGCTCCAGGGTTCGGAGACATCCTGGGCT
11 MIR129-2 NR_029697 TSS200 chr11:
43602545–
43603215
Island
miR-152 cg05687686 CAGCTTCGGCATATTTGGCGGAG
CCGGGAAGGCCCGGAGCGCAAGAAGGCAT
CGCAGCCT[CG]CAGCA
GATCTGAAAGGGTTGTGGGCGGG
GGGCTCATTTTCGCCGGATTTCTTTTCCGTGT
2 MIR1258;
ZNF385B
NR_031659;
NM_152520
TSS1500;
TSS1500
chr2:
180725717–
180726465
S_Shore
miR-193b cg09918657 AGTGGCGTTTCTGGTTTCTCTTTG
CTTCCAATCCCCACCAAGCGGAG
CGTTGGAATGCGC[CG]CTTATG
TCCTCTGAGGACACATCCATATTT
ATAATTTATTTTTAGGAGAAGTTGTGAAAA
16 MIR193B NR_030177 TSS1500 chr16:
14395604–
14397075
S_Shore
miR-663a cg08304190 GCCTCACGAGCCCCTGGTCCCGCCA
CCGGGGCCCCGAAGCGACCACAG
CCACAAACTCAA[CG]CCAGGGCCACA
TCGCTCGTGATTCTCGTCCATCCTCCGAC
CCGGTCCCGCTCCGGGAGAC
20 MIR663 NR_030386 TSS200 chr20:
26188638–
26190348
Island
miR-1258 cg05850656 ACTGCTCCAGAGCCCGAGTCGGAGTGTA
TCACAGAACCTGGGCCGGGGGGGACA
GCGGGC[CG]AGCCTCCTTCTTCCAGCT
GATCCCTGGCCGGGCTGGACCTGCGCTA
TCAGCGCGCCCCCA
17 MIR152;
COPZ2
NR_029687;
NM_016429
TSS200;
Body
chr17:
46114573–
46115059
Island
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men carrying indolent/non-life threatening tumors [13].
Thus, a strong recommendation against serum PSA-based
PCa screening has been issued [14], prompting the search
for more effective biomarkers allowing for better risk
stratification of PCa suspects. Herein, we aimed to tackle this
clinical quest through discovery and preliminary validation
of novel biomarkers for PCa detection and prognostication,
using methylation analysis of microRNAs gene promoters.
Fig. 2 Box-plots and ROC curves for miR-34b/c, miR-129-2, miR-152, miR-193b, miR-663a and miR-1258 promoter methylation levels in
morphologically normal prostate tissue (MNPT) and malignant (PCa) prostatic tissues from Cohort #1
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Owing to our previous experience in DNA methyla-
tion analysis of PCa [6, 11], we searched for altered
methylation patterns at the promoter regions of micro-
RNAs deregulated in PCa. This information was then
used to develop novel biomarkers, instead of microRNA
expression levels, as previously attempted by other
researchers [15]. Indeed, DNA methylation is easier to
assess than microRNA expression, it is more specific
and, importantly, more stable. Moreover, because micro-
RNAs downregulation in cancer is more common than
upregulation, it seemed likely that aberrant promoter
methylation might constitute an underlying mechanism,
similar to protein-coding genes [16]. Although several
strategies might be used to identify microRNAs puta-
tively downregulated due to promoter hypermethylation,
high-throughput technologies such as methylation-array
analysis are able to simultaneously pinpoint putative
candidates [17] and the reliability of the results might be
readily assessed through analysis of well-known hyper-
methylated loci. Indeed, results of the methylation array
experiments confirmed the high prevalence of GSTP1
and APC promoter methylation (data not shown), as we
previously demonstrated in PCa [18]. To increase the
likelihood of finding robust candidate biomarkers, we
used stringent conditions based on high fold-variation of
methylation levels between cancerous and non-
cancerous tissue samples. From methylation-array ana-
lysis, six candidate microRNAs, putatively deregulated
by promoter hypermethylation were identified. MiR-
1258, miR-193b and miR-34b/c were the most promising
candidates, displaying substantial PCa-specificity com-
pared with other urinary tract tumors, an attractive
feature for testing in bodily fluids. MiR-129-2 and miR-
663a showed modest results and their inability to
discriminate PCa from bladder cancer rendered it un-
suitable for testing in urine samples.
Table 4 Validity estimates for miR’s promoter methylation as
markers for PCa in Cohort #1
microRNA Sensitivity %
(n positive/n total)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%)
miR-34b/c 94.4 (170/180) 86.7 98.8 56.5 93.8
miR-129-2 90.6 (163/180) 86.7 98.8 43.3 90.3
miR-152 79.4 (143/180) 86.7 98.6 26.0 80.0
miR-193b 90.0 (162/180) 100.0 100.0 45.5 90.8
miR-663a 84.4 (152/180) 100.0 100.0 34.9 85.6
miR-1258 97.8 (176/180) 100.0 100.0 78.9 97.9
PCa Prostate cancer; PPV positive predictive value; NPV negative predictive value
Fig. 3 Distribution of methylation levels of microRNAs according to Gleason score and pathological stage in the series of patients submitted to
radical prostatectomy (Cohort #1)
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Association between promoter methylation levels in
tumor tissue samples and standard clinicopathological vari-
ables was also assessed. Higher miR-129-2 promoter methy-
lation levels associated with higher GS and stage, suggesting
prognostic value. MiR-34b/c, miR-663a and miR-1258
methylation levels also associated with pathological stage,
but higher diagnostic performance underscores the potential
for detecting PCa at early stages instead of prognostication,
as we previously reported for EFEMP1 promoter methyla-
tion [19]. Nevertheless, in this series of radical prostatecto-
mies (Cohort #1) higher miR-129-2 methylation conveyed
independent prognostic information, although only for DSS.
Importantly, these results are in line with previous observa-
tions concerning the association of higher gene promoter
methylation levels with clinicopathological features of more
aggressive disease [11, 20].
Urine is a key sample to evaluate DNA methylation bio-
markers for PCa, as it is readily collected and biomarkers
are diluted to a smaller extent than in plasma, providing
higher sensitivity[21]. Nevertheless, the amount of DNA
potentially deriving from prostatic cells is variable, usually
low, entailing the use of a panel with limited number of
biomarkers. Thus, only miR-34b/c, miR-193b and mir-
1258, were tested in urine samples (Cohort #3). From
these, Mir-193b was previously shown to be aberrantly
methylated in PCa cell lines as well as in primary tumors,
but no data is available regarding its performance as PCa
detection biomarker [22, 23]. Indeed, Mir-193b performed
best, with high AUC, sensitivity, specificity and PPV,
whereas miR-34b/c performance was more modest.
Intriguingly, miR-1258, which showed the best perform-
ance in tissue samples (Cohort #1), displayed a strikingly
different result in urines as its methylation levels were
higher in controls than in PCa patients. The reason for
this discrepant result is not immediately apparent, but it
might be due to high miR-1258 promoter methylation in
non-epithelial cells, such as leucocytes, which are rela-
tively more abundant in urine than in tumor tissue
Table 5 Validity estimates for miR’s promoter methylation as
markers for PCa in urine samples (Cohort #3)
microRNA Sensitivity %
(n positive/n total)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%)
miR-34b/c 89.5 (85/95) 47.8 78.0 68.8 75.9
miR-193b 91.6 (87/95) 95.7 97.8 84.6 92.9
miR-34b/c+
miR-193b
90. 5% (86/95) 97.8 98.9 83.3 92.9
Fig. 4 Box-plots and ROC curves of miR-34b/c, miR-193b and miR-1258 promoter methylation levels across urine sediments of controls (HD) and
prostate cancer patients (PCa) from Cohort #3. Receiver operator characteristic (ROC) curves were constructed to evaluate the performance of the
gene promoter methylation panel (miR-34b/c+miR-193b)
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samples. Moreover, median miR-1258 promoter methyla-
tion levels in urines from PCa were substantially inferior
to those of miR-193b, impairing the robustness of the
assay. It should be recalled that, contrarily to other stud-
ies, the urine samples we used were not collected follow-
ing DRE or prostatic massage, which are usually employed
in an attempt to increase sensitivity. Studies dealing with
PCa biomarkers in urine vary in the method of urine col-
lection and the real impact of prostatic massage has never
been evaluated [24]. It could be argued that the distance
from the peripheral zone to the urinary tract flow may
render urinary based tests less sensitive, which would be
an important issue since most malignancies arise from this
zone. Nevertheless, studies on PCA3 did not find a differ-
ence in the levels of this biomarker between patients with
peripheral versus transitional zone PCa [25, 26].
Currently, the performance of serum PSA and urinary
PCA3, the only biomarkers approved for clinical use is ra-
ther limited. The reported performance of serum PSA as
PCa biomarker is somewhat modest, with AUC ranging
from 0.54 to 0.70 [27, 28]. Even other serum PSA-derived
measurements, like PSA-density, free PSA percentage and
PSA-velocity have not significantly improved performance
[28]. Nonetheless, PCA3, which was reported to perform
better than serum PSA both in urine and ejaculates but has
not been approved for population-based screening, displays
AUCs varying from 0.66 to 0.79 [27–30]. Additionally,
although miRs’ expression has been extensively investigated
in liquid biopsies, available data for urine samples is rather
limited. Nevertheless, an AUC of 0.74 was reported for
miR-107 [31] and simultaneous quantification of miR-107
and miR-574-3p in urine showed an AUC of 0.83, for PCa
cancer detection [32]. We should emphasize that in our
dataset, urinary miR-193b promoter methylation (AUC=
0.96) outperformed not the only currently approved clinical
biomarkers, but also the previously mentioned miRs, con-
stituting a promising tool for non-invasive PCa detection.
Because a major goal of this study was to discriminate
clinically aggressive from indolent PCa, it was critical to
test the prognostic value of microRNAs in a pre-
therapeutic setting, which was accomplished in series of
prospectively collected prostate biopsies (Cohort #3). In
univariable analysis, most standard clinicopathological pa-
rameters associated with DFS and DSS, clinically validating
this dataset. The same was demonstrated for higher miR-
129-2 and miR-34b/c promoter methylation levels. The
CAPRA score, however, only associated with DSS but not
DFS. This was unexpected as its determination at diagnosis
associated with DFS in patients with clinically localized dis-
ease submitted to RP [12]. Notwithstanding, our prostate
biopsy series included PCa at diverse clinical stages, sub-
mitted to different therapeutic modalities (RP, radiotherapy,
androgen-deprivation therapy), which might explain the
apparent flaw of CAPRA score. In multivariable analysis,
Fig. 5 a - Disease-free survival (DFS) curves based on pathological stage (upper left panel) and Gleason score (upper right panel), and miR-129-2
methylation levels (lower panel) in Cohort #1. b - Disease-free survival (DFS) curves based on clinical stage (upper left panel) and Gleason score
(upper right panel), miR-34b/c (lower left) and miR-129-2 (lower right) methylation levels in Cohort #2
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only clinical stage, amongst all clinicopathological parame-
ters, retained independent prognostic value, both for DFS
and DSS. Remarkably, high miR-34b/c promoter methyla-
tion levels also predicted shorter DFS and DSS, suggesting
that it might constitute a useful PCa prognostic biomarker.
These results suggest that high miR-34b/c promoter
methylation levels identify clinically aggressive PCa, irre-
spective of disease extent at diagnosis.
Fig. 6 A - Disease-specific survival (DSS) curves based on pathological stage (upper left), Gleason Score (upper right), and miR-129-2 methylation
levels (lower) in Cohort #1. B - Disease-specific survival (DSS) curves based on clinical stage (upper left), Gleason Score (upper center) CAPRA Score
(upper left), miR-34b/c (lower left) and miR-129-2 (lower-right) methylation levels in Cohort #2
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It should be acknowledged that in spite of the excellent
diagnostic performance of miR-193b promoter methyla-
tion in urine, additional patient sets must be tested.
Furthermore, a larger cohort of patients submitted to
biopsy and subjected to different therapies is required to
further validate our observations. Ultimately, we plan to
develop a multiplex assay to simultaneously assess miR-
193b, miR-129-2 and miR34b/c promoter methylation,
allowing for diagnostic and prognostic assessment of PCa
suspects in a single analysis.
Conclusion
Through genome-wide screening, a set of methylation-
based PCa biomarkers was identified and validated. MiR-
193b demonstrated high sensitivity and specificity for
detection of PCa, both in tissue and urine, whereas high
miR-129-2 and miR-34b/c methylation levels independently
predicted for shorter DSS and DFS or DSS, respectively. If
confirmed in larger and independent datasets, quantitative
promoter methylation of selected miRs might provide
useful tools for clinical management of PCa patients. The
authors would like to extend their appreciation to all the
patients and control subjects that kindly provided the
biological samples for this study.
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Table 6 Cox regression analysis assessing the potential of clinical
and epigenetic variables in the prediction of disease-specific survival
and disease-free survival in the Cohort #1 and Cohort #2
Cohort #1
Disease-specific survival – Cox
regression analysis
Disease-free survival – Cox
regression analysis
Variable HR CI (95%) P Variable HR CI (95%) P
Gleason Score Gleason Score
<7 1
≤7 1 7 3.96 1.76–8.91 0.001
>7 18.97 4.32–83.351 <0.001 >7 7.73 2.85–21.0 <0.001
miR–129-2 PSA
≤ P75 1 <10 1
> P75 6.12 1.56–24.07 0.009 ≥10 1.87 1.07–3.26 0.027
Cohort #2
Disease-specific survival – Cox
regression analysis
Disease-free survival – Cox
regression analysis
Variable HR CI (95%) P Variable HR CI (95%) P
Clinical
stage
Clinical
stage
II 1 II 1
III/IV 9.64 2.60-35.8 <0.001 III/IV 2.57 1.18-5.60 0.018
miR-34b/c miR-34b/c
≤ P75 1 ≤ P75 1
> P75 3.84 1.27–11.6 0.017 > P75 2.76 1.24–6.15 0.013
HR hazard ratio, CI confidence interval
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